Welcome to the first Drug Pipeline Insights Report for 2024
Read the report for a review of:
- First approved drug for negative symptoms of schizophrenia
- First-in-class treatment for pulmonary arterial hypertension
- First FDA-approved drug for nonalcoholic steatohepatitis (NASH)
View the first Drug Pipeline Insights Report for 2024
Don't want to read the full report? View the summary
Related healthcare insights
Guide
Read the most recent quarterly reports on new drugs coming down the pipeline.
Article
Explore innovations custom built for today’s specialty challenges.
Video
Hear how the industry’s most transparent and independent Pharmacy & Therapeutics Committee evaluates drugs for the Optum Rx formulary.